Journal
RSC MEDICINAL CHEMISTRY
Volume 13, Issue 11, Pages 1300-1321Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d2md00206j
Keywords
-
Funding
- National Natural Science Foundation of China [22071175]
- Beijing Municipal Science & Technology Commission [Z211100003321007]
Ask authors/readers for more resources
Drugs containing pyrazole nucleus have shown a broad spectrum of biological activities, including anti-inflammatory, antipsychotic, and analgesic effects. Research suggests that drugs with pyrazole nucleus may exhibit better pharmacokinetics and pharmacological effects compared to drugs containing similar heterocyclic rings.
Pyrazole is a five-membered heterocycle bearing two adjacent nitrogen atoms. Both pharmaceutical agents and natural products with pyrazole as a nucleus have exhibited a broad spectrum of biological activities. In the last few decades, more than 40 pyrazole-containing drugs have been approved by the FDA for the treatment of a broad range of clinical conditions including celecoxib (anti-inflammatory), CDPPB (antipsychotic), difenamizole (analgesic), etc. Owing to the unique physicochemical properties of the pyrazole core, pyrazole-containing drugs may exert better pharmacokinetics and pharmacological effects compared with drugs containing similar heterocyclic rings. The purpose of this paper is to provide an overview of all the existing drugs bearing a pyrazole nucleus that have been approved or in clinical trials, involving their pharmacological activities and SAR studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available